Yidu Tech, Inc. (2158) AI Stock Analysis

• Market Cap: HK$4.73B
• Dividend Yield: N/A
• Average Volume (3M): 6.50M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.77
• Revenue Growth: -4.99%
• EPS Growth: 47.18%
• Country: HK
• Employees: 866
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.01
• Shares Outstanding: 1,070,634,900
• 10 Day Avg. Volume: 6,345,530
• 30 Day Avg. Volume: 6,499,248
• PEG Ratio: 1.23
• Price to Book (P/B): 1.55
• Price to Sales (P/S): 8.53
• P/FCF Ratio: -17.38
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.62
• Revenue Forecast (FY): HK$6.20B

• Rating: 39 Underperform
• Price Target: HK$4.50 ▼(-19.35% Downside)

Yidu Tech, Inc. faces significant financial and technical challenges. The most impactful factors are the company's negative profitability and bearish technical indicators. The valuation is also concerning with a negative P/E ratio. These factors collectively result in a low overall stock score.

Positive Factors

Balance Sheet Health

A low debt-to-equity ratio indicates conservative leverage, providing financial stability and flexibility for future investments.

Cash Generation Ability

Improved free cash flow growth suggests better cash management, which can support operational needs and strategic investments.

Industry Position

As a leader in healthcare technology, Yidu Tech benefits from strong market position and potential for growth in a data-driven healthcare sector.

Negative Factors

Revenue Growth Challenges

Negative revenue growth indicates challenges in market expansion and sales execution, impacting long-term business sustainability.

Profitability Issues

Ongoing profitability issues reflect cost management challenges, which can hinder reinvestment and shareholder returns.

Operating Cash Flow

Negative operating cash flow indicates operational inefficiencies, posing risks to liquidity and financial health over time.

Yidu Tech, Inc. Business Overview & Revenue Model

Company Description

Yidu Tech, Inc. is a leading healthcare technology company based in China, specializing in providing data-driven solutions for the healthcare sector. The company integrates artificial intelligence and big data analytics to enhance the efficiency and quality of healthcare delivery. Yidu Tech's core products include medical data platforms, AI-driven diagnostic tools, and healthcare management systems, which cater to hospitals, healthcare providers, and pharmaceutical companies.

How the Company Makes Money

Yidu Tech generates revenue primarily through its subscription-based model for its data platforms and healthcare management systems, charging healthcare institutions for access and usage. Additionally, the company earns revenue from licensing its AI diagnostic tools and analytics software to hospitals and clinics. Strategic partnerships with healthcare providers and pharmaceutical companies also contribute to its earnings, as these collaborations often lead to joint projects and shared revenue opportunities. Furthermore, Yidu Tech's involvement in research and development projects funded by governmental and private organizations helps bolster its financial standing.

Yidu Tech, Inc. Financial Statement Overview

Summary

Yidu Tech, Inc. faces challenges in revenue growth and profitability, with declining revenue and negative profit margins. The balance sheet is stable with low leverage, but profitability needs improvement. Cash flow management is crucial, as operating cash flow remains negative.

Income Statement

Yidu Tech, Inc. has experienced declining revenue growth, with a negative growth rate of -8.34% in the most recent year. The company also faces challenges in profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin has decreased from the previous year, indicating pressure on cost management. Overall, the income statement reflects a need for improvement in revenue generation and cost control.

Balance Sheet

The balance sheet shows a low debt-to-equity ratio of 0.03, indicating conservative leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio remains strong at approximately 83.6%, suggesting a solid equity base relative to total assets. Despite the low leverage, the company needs to improve profitability to enhance shareholder returns.

Cash Flow

Yidu Tech, Inc. has shown a significant increase in free cash flow growth, but the operating cash flow remains negative, indicating operational challenges. The free cash flow to net income ratio is positive, suggesting that the company is generating cash relative to its net losses. However, the negative operating cash flow to net income ratio highlights the need for better cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	714.98M	714.98M	807.08M	804.70M	1.24B	867.04M
Gross Profit	239.18M	239.18M	339.44M	274.50M	396.89M	327.34M
EBITDA	-274.44M	-89.62M	-170.77M	-579.98M	-715.70M	-3.65B
Net Income	-117.79M	-117.79M	-194.94M	-627.97M	-762.32M	-3.70B
Balance Sheet
Total Assets	4.69B	4.69B	4.82B	4.91B	4.72B	5.25B
Cash, Cash Equivalents and Short-Term Investments	3.30B	3.30B	3.70B	3.75B	3.77B	4.63B
Total Debt	129.54M	129.54M	95.20M	14.13M	52.16M	26.43M
Total Liabilities	711.37M	711.37M	732.21M	755.36M	715.34M	497.71M
Stockholders Equity	3.92B	3.92B	4.02B	4.08B	3.99B	4.73B
Cash Flow
Free Cash Flow	-350.62M	-350.78M	-367.20M	-374.60M	-672.14M	-350.73M
Operating Cash Flow	-248.81M	-248.81M	-326.38M	-357.01M	-614.68M	-331.68M
Investing Cash Flow	116.71M	116.71M	466.90M	-2.34B	3.39B	-3.87B
Financing Cash Flow	20.04M	20.04M	82.21M	361.45M	-35.23M	4.26B

Yidu Tech, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.58
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2158, the sentiment is Negative. The current price of 5.58 is above the 20-day moving average (MA) of 5.12, above the 50-day MA of 5.58, and below the 200-day MA of 6.00, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 43.99 is Neutral, neither overbought nor oversold. The STOCH value of 20.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2158.

Yidu Tech, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1763	79 Outperform	HK$6.75B	14.73	8.59%	2.68%	13.59%	6.31%
2877	73 Outperform	HK$6.21B	6.96	10.85%	6.14%	-20.64%	-25.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2159	46 Neutral	HK$324.80M	-7.09	-35.99%	―	-5.38%	63.93%
2616	42 Neutral	HK$8.89B	-18.93	-95.84%	―	-55.64%	-158.67%
2251	40 Neutral	HK$1.10B	-6.00	-12.97%	―	-32.17%	-1.20%
2158	39 Underperform	HK$4.73B	-55.24	-2.23%	―	-4.99%	47.18%

Yidu Tech, Inc. Corporate Events

Yidu Tech Inc. Announces Share Award Grant to Drive Long-term Growth

Yidu Tech Inc. announced the grant of 1,958,000 share awards under its Post-IPO Share Award Scheme, representing approximately 0.18% of its total issued shares. This initiative is designed to incentivize key personnel by aligning their performance with the company’s strategic goals, with shares vesting over a period from April 2026 to April 2029. The company has established a performance appraisal mechanism to ensure that the award grantees meet specific targets, thereby contributing to the long-term growth and development of the company.

Yidu Tech Reports Revenue Growth and Reduced Losses Amidst Industry Expansion

Yidu Tech Inc. reported an 8.7% increase in revenue for the six months ending September 2025, driven by favorable industry policies and increased market demand. The company’s strategic focus on core clients and business segments, along with improved operational efficiency, resulted in a significant reduction in operating losses by 71.0% and a 72.0% decrease in overall losses. The company is leveraging its expertise in medical AI to build intelligent systems and infrastructure, positioning itself to capture future market opportunities.

Yidu Tech Inc. Schedules Board Meeting to Review Interim Results

Yidu Tech Inc. has announced a Board meeting scheduled for November 27, 2025, to review and approve the unaudited consolidated interim results for the six months ending September 30, 2025, and to consider the payment of an interim dividend. This meeting is significant as it will provide insights into the company’s financial health and potential returns for shareholders, impacting its operational and market positioning.

Yidu Tech Inc. Engages in Total Return Swap to Hedge Share Price Exposure

Yidu Tech Inc. has announced that a subsidiary has entered into a Total Return Swap (TRS) transaction with a counterparty, with a maximum equity notional amount of approximately HK$54,404,700. The TRS transaction, which is set for a term of approximately three years, is designed to hedge the company’s exposure to future share price appreciation, particularly in relation to its Post-IPO Share Award Scheme. The board believes the transaction terms are fair and reasonable, serving the interests of the company and its shareholders. The transaction is not subject to reporting or approval requirements under the Listing Rules, as it does not meet the applicable percentage ratios.

Yidu Tech Secures Phase III Clinical Study Project for AI-Driven Eye Drop

Yidu Tech Inc. announced that its associate, Tianjin Happy Life Technology Co., Ltd., has successfully secured a bid for a Phase III Clinical Study Project of Recombinant Human Neurogenesis Factor (SMR001) Eye Drop from Shandong Yandu Biotechnology Co., Ltd., valued at approximately RMB55.8 million. This development underscores Yidu Tech’s commitment to improving healthcare service efficiency and accessibility through AI-driven solutions, reinforcing its position in the healthcare industry by enabling precise decision-making and accelerating pharmaceutical development.